engleski

Transient hypophosphatemia as possible adverse outcome after iron deficiency anemia treatment with ferric carboxymaltose-single center experience

Ferric carboxymaltose (FCM) is an iron formulation for parenteral treatment of iron defficiency anemia (IDA). The primary aim of this paper is to study the frequency of hypophosphatemia after FCM therapy in female patients with IDA. Thirty two female patients examined for IDA at the Hematology and Oncology Department of one General Hospital were included in the study. The inclusion criteria were hemoglobin < 110 g / L, transferrin saturation< 50%, ferritin < 30 ng/mL and ineffective oral iron therapy. The difference between hemoglobin values before FCM therapy and 6 weeks after therapy is statistically significant. The onset of the asymptomatic hypophosphatemia was observed in 17 patients (61%) two weeks after the FCM therapy. Only one patient (3.7%) had severe asymptomatic hypophosphatemia (serum phosphate < 0.3 mmol/L). Prolonged hypophosphatemia (six weeks after FCM therapy) was observed in five patients (17, 9%), of which only one patient had initially hypophosphatemia. The difference between the phosphate values measured two weeks after the FCM therapy and the phosphate values at the first and last control examination is statistically siginificant. The main conclusion of this paper is that serum phosphate values should be routinely measured before and after parenteral FCM therapy.

ferric carboxymaltose ; hypophosphatemia ; iron defficiency anemia

nije evidentirano